HOME ·

CSPC PHARMA

CSPC Pharmaceutical (01093.HK): Paliperidone Palmitate Injection Approved for Marketing; Indicated for Schizophrenia Acute and Maintenance Treatment
Tags：
CSPC PHARMA01093.HK
2026-07-24
CSPC PHARMA (01093.HK): NDA for Envi Trastuzumab Injection Accepted by NMPA
Tags：
CSPC PHARMA01093.HKNew Drug Application
2026-07-17
CSPC PHARMA(01093.HK): Phase II Clinical Trial of SYH2070 Injection for Mixed Hyperlipidaemia Initiated at First Clinical Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-07-07
CSPC PHARMA(01093.HK): Enters Collaboration, Option and Licence Agreement with AstraZeneca for siRNA Drug Development with USD30 Million Upfront Payment
Tags：
CSPC PHARMA01093.HKAstraZeneca
2026-07-02
CSPC PHARMA(01093.HK): Phase III Study of Anistolimab Combined with HB1801 for HER2-positive Advanced Breast Cancer Meets Primary Endpoint
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-06-10
CSPC PHARMA(01093.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 859.79 million, YoY decrease of 41.83%
Tags：
CSPC PHARMA01093.HK
2026-05-27
CSPC PHARMA(01093.HK): Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials for Advanced Solid Tumors
Tags：
CSPC PHARMA01093.HKClinicalTrialApproval
2026-04-15